Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-up
Clinical trial NCT06178770 · COMPLETED
Trial details
- NCT number
- NCT06178770
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2021-12-01
- Primary completion
- 2022-12-12
- Enrollment
- 414
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.